Cargando…
Hyperphosphatemia and its relationship with blood pressure, vasoconstriction, and endothelial cell dysfunction in hypertensive hemodialysis patients
BACKGROUND: Hyperphosphatemia occurs frequently in end-stage renal disease patients on hemodialysis and is associated with increased mortality. Hyperphosphatemia contributes to vascular calcification in these patients, but there is emerging evidence that it is also associated with endothelial cell d...
Autores principales: | Jung, Jinwoo, Jeon-Slaughter, Haekyung, Nguyen, Hang, Patel, Jiten, Sambandam, Kamalanathan K., Shastri, Shani, Van Buren, Peter Noel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396889/ https://www.ncbi.nlm.nih.gov/pubmed/35999520 http://dx.doi.org/10.1186/s12882-022-02918-0 |
Ejemplares similares
-
Extracellular Volume Overload and Increased Vasoconstriction in Patients With Recurrent Intradialytic Hypertension
por: Van Buren, Peter Noel, et al.
Publicado: (2016) -
Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis
por: Vasantha, J., et al.
Publicado: (2011) -
NaPi-IIb Inhibition for Hyperphosphatemia in CKD Hemodialysis Patients
por: Maruyama, Sonomi, et al.
Publicado: (2020) -
Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis
por: Savica, Vincenzo, et al.
Publicado: (2008) -
Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients
por: Zeng, Qian, et al.
Publicado: (2023)